Clinical trials: Lung Cancer, completed
Hematological Neoplasms, Non-Hodgkin's Lymphoma
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
This is a Phase 1, open-label, multicenter, randomized, 2-stage crossover study consisting of 2 phases: Stage I - Pharmacokinetics (Bioequivalence), with an Extension Stage II - Pharmacokinetics (Food Effect) with an Extension…
- Conditions
- Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma
- Trial name
- NCT02223052
- Testing
- CC-486, Vidaza
- Where
- 10 sites in United States
- Volunteers
- 89 people
- Sponsor
- Celgene
Lung Cancer
Dynamic Magnetic Resonance Imaging (MRI) for Lung Tumor Motion and Lung Function (GCC 0943)
Radiation treatment for each patient with cancer is designed based on CT scans. We know that tumors in the chest and abdomen move when you breathe.
- Trial name
- NCT01016938
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Maryland, Baltimore
Non-small Cell Lung Cancer
A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy of anti-emetic drug Aprepitant upon the combination chemotherapy of nedaplatin and docetaxel for non-small cell lung cancer (NSCLC).
- Trial name
- NCT02364804
- Testing
- Aprepitant
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Shiga University
Non Small Cell Lung Cancer
First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin
The research study is testing the investigational drug necitumumab (IMC-11F8) in the treatment of advanced non-small cell lung cancer.
- Trial name
- SQUIRE (NCT00981058)
- Testing
- Necitumumab, Gemcitabine, Cisplatin
- Where
- 182 sites in United States, Australia and 24 more
- Volunteers
- 1,093 people
- Sponsor
- Eli Lilly and Company
Cancer, Lung
Effects of Transcutaneous Electrical Nerve Stimulation in Post-operative Lung Cancer
Among all cancers, lung cancer is the most common disease on the planet, accounting for 13% of the cases, and leading the number of deaths from malignant diseases.
- Trial name
- NCT03903276
- Testing
- rehabilitation
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Universidade Metodista de Piracicaba
Lung Cancer
BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC
Primary Objective: To determine the 8 week progression-free survival rate (i.e. disease control rate) in patients with advanced NSCLC who have failed at least one prior chemotherapy regimen.
- Trial name
- NCT00410189
- Testing
- ZD6474
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma of the Lung
A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
The primary objective of this study is to compare the effect of farletuzumab versus placebo in combination with either a platinum agent (carboplatin) with paclitaxel or a platinum agent (carboplatin or cisplatin) with pemetrexed…
- Trial name
- NCT01218516
- Testing
- Farletuzumab, Carboplatin, Paclitaxel
- Where
- 93 sites in United States, Australia and 6 more
- Volunteers
- 130 people
- Sponsor
- Morphotek
Lung Cancer, Non-Small-Cell Lung Carcinoma
A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients
This study will determine the objective response rate in chemotherapy naive non-small cell lung cancer patients with advanced disease.
- Trial name
- NCT00201825
- Testing
- Capecitabine, Docetaxel
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Tony Bekaii-Saab
Non Small Cell Lung Cancer
Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC
This is a Phase I, open-label, 2-part study in patients with a confirmed diagnosis of epidermal growth factor receptor (EGFR) mutation positive (EGFRm+) non-small cell lung cancer (NSCLC), who have progressed following prior…
- Trial name
- NCT02908750
- Testing
- Fexofenadine tablet dosing, Osimertininb tablet dosing
- Where
- 7 sites in France, South Korea and 1 more
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Solid Tumor, Adult
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
T Cell Receptor-engineered T-cell therapy (TCR T-cell therapy) offers a potentially transformative approach to treating cancer, but is currently limited by the lack of known targets (Maus and June, 2016; Ping et al., 2018).
- Trial name
- NCT05230186
- Testing
- Tumor Biopsy
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- TScan Therapeutics, Inc.
Extensive Stage Small Cell Lung Cancer
Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Oblimersen may make tumor cells more sensitive to chemotherapy drugs.
- Trial name
- NCT00017251
- Testing
- oblimersen sodium, carboplatin, etoposide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, NSCLC
18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy
Study the EFS and OS according to 18FDG PET in patients with melanoma or non small cell lung cancer treated by immunotherapy.
- Conditions
- Melanoma, NSCLC, Positron-Emission Tomography, Immunotherapy
- Trial name
- IMMUNOPET (NCT03741231)
- Where
- 3 sites in France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Brest
Lung Neoplasms, Lung Cancer
Lung Nodule Prospective Database
Lung cancer is one of the most common cancers in the Singapore population, being the 2nd most commonly diagnosed cancer amongst males and 3rd most commonly diagnosed cancer amongst females.
- Conditions
- Lung Neoplasms, Lung Cancer, Lung Adenocarcinoma
- Trial name
- NCT03922828
- Testing
- CT scans
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- Singapore General Hospital
Lung Cancer, Sleep-Disordered Breathing
Sleep Apnea in Lung Cancer: A Prospective Study
The study seeks to determine the prevalence of sleep disordered breathing in a population of patients diagnosed with lung cáncer.
- Trial name
- SAIL (NCT02764866)
- Testing
- Sleep testing
- Where
- Spain
- Volunteers
- 83 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Molecular Imaging
EGFR Molecular Classification In Vivo
The investigators developed 18F-IRS as a targeted molecular imaging agent for noninvasive and repeatable detecting EGFR-activating mutational status.
- Trial name
- NCT03031522
- Testing
- 18F-IRS
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Harbin Medical University
Non-Small Cell Lung Cancer, Renal Cell Cancer
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers.
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer
- Trial name
- NCT03454451
- Testing
- CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab
- Where
- 27 sites in United States, Australia
- Volunteers
- 117 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Advanced Malignancy, Advanced Solid Tumors
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Neoplasm, Metastasis
- Trial name
- SDX-0101 (NCT02743637)
- Testing
- SDX-7320
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- SynDevRx, Inc.
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung, Synchronous Neoplasms
Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma
Non-small cell lung cancer (NSCLC) is the most frequent neoplasm worldwide and also represents the main cause of cancer death. However, it represents the main cause of death by cancer.
- Trial name
- NCT02805530
- Testing
- First line systemic treatment, Radical treatment, radiation therapy
- Where
- Mexico
- Volunteers
- 36 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Head and Neck Squamous Cell Carcinoma, Lung Cancer
A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer
The study is an open label, multicentric, Phase I/II trial aiming to evaluate the safety, the clinical activity and abscopal anti-tumor effects of a therapeutic strategy associating Durvalumab in conjunction with SBRT or…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Lung Cancer, Oesophageal Cancer
- Trial name
- ABIMMUNE (NCT03212469)
- Testing
- Durvalumab, Tremelimumab, SBRT
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.